Toxic Shock Syndrome. Major Advances in Pathogenesis, But Not Treatment.

Critical Care Clinics

Volumn 29, Issue 3, 2013, Pages 651-675

  Low, Donald E ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cytokine storm; Group A streptococcus; Necrotizing fasciitis; Staphylococcus aureus; Superantigen; Toxic shock syndrome

Indexed keywords

AZUROCIDIN; CLINDAMYCIN; IMMUNOGLOBULIN G; M PROTEIN; MONOCLONAL ANTIBODY CD28; PENICILLIN DERIVATIVE; RESISTIN; STAPHYLOCOCCUS ENTEROTOXIN;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE STORM; DEBRIDEMENT; DIAGNOSTIC TEST; DISEASE ASSOCIATION; GROUP A STREPTOCOCCAL INFECTION; HUMAN; INCIDENCE; INFLUENZA; LUNG INJURY; MENSTRUAL CYCLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

CYTOKINE STORM; GROUP A STREPTOCOCCUS; NECROTIZING FASCIITIS; STAPHYLOCOCCUS AUREUS; SUPERANTIGEN; TOXIC SHOCK SYNDROME;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CYTOKINES; FASCIITIS, NECROTIZING; HUMANS; IMMUNOGLOBULINS; INCIDENCE; MENSTRUAL HYGIENE PRODUCTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, BACTERIAL; SHOCK, SEPTIC; SKIN DISEASES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; WOUND INFECTION;

EID: 84880028228     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2013.03.012     Document Type: Review

References (90)

1. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995, 8:411-426.
2. Stevens F.A. The occurrence of Staphylococcus aureus infection with a scarlitiniform rash. JAMA 1927, 88:1957-1958.
3. Todd J., Fishaut M., Kapral F., et al. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet 1978, 2:1116-1118.
4. Shands K.N., Schmid G.P., Dan B.B., et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. NEngl J Med 1980, 303:1436-1442.
5. Davis J.P., Chesney P.J., Wand P.J., et al. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. NEngl J Med 1980, 303:1429-1435.
6. Schlievert P.M., Osterholm M.T., Kelly J.A., et al. Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome. Ann Intern Med 1982, 96:937-940.
7. Bonventre P.F., Linnemann C., Weckbach L.S., et al. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. JInfect Dis 1984, 150:662-666.
8. Cone L.A., Woodward D.R., Schlievert P.M., et al. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. NEngl J Med 1987, 317:146-149.
9. Bartter T., Dascal A., Carroll K., et al. "Toxic strep syndrome": manifestation of group A streptococcal infection. Arch Intern Med 1988, 148:1421-1424.
10. Stevens D.L., Tanner M.H., Winship J., et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. NEngl J Med 1989, 321:1-7.
11. MacDonald K.L., Osterholm M.T., Hedberg C.W., et al. Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA 1987, 257:1053-1058.
12. Centers for Disease Control Update: toxic-shock syndrome-United States. MMWR Morb Mortal Wkly Rep 1983, 32:398.
13. Schlievert P.M., Tripp T.J., Peterson M.L. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. JClin Microbiol 2004, 42:2875-2876.
14. DeVries A.S., Lesher L., Schlievert P.M., et al. Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. PLoS One 2011, 6:e22997.
15. Durand G., Bes M., Meugnier H., et al. Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1gene responsible for hospital- and community-acquired infections in France. JClin Microbiol 2006, 44:847-853.
16. Rice T.W., Rubinson L., Uyeki T.M., et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012, 40:1487-1498.
17. Katz A.R., Morens D.M. Severe streptococcal infections in historical perspective. Clin Infect Dis 1992, 14:298-307.
18. Carapetis J., Robins-Browne R., Martin D., et al. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypeable clone. Clin Infect Dis 1995, 21:1220-1227.
19. Lamagni T.L., Darenberg J., Luca-Harari B., et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. JClin Microbiol 2008, 46:2359-2367.
20. Demers B., Simor A.E., Vellend H., et al. Severe invasive group A streptococcal infections in Ontario, Canada; 1987-1991. Clin Infect Dis 1993, 16:792-800.
21. Steer A.C., Lamagni T., Curtis N., et al. Invasive group a streptococcal disease: epidemiology, pathogenesis and management. Drugs 2012, 72:1213-1227.
22. Carapetis J.R., Steer A.C., Mulholland E.K., et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5:685-694.
23. Hoge C.W., Schwartz B., Talkington D.F., et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 1993, 269:384-389. [published erratum appears in JAMA 1993 Apr 7;269(13):1638] [see comments].
24. Aziz R.K., Kotb M. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 2008, 14:1511-1517.
25. Steer A.C., Law I., Matatolu L., et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009, 9:611-616.
26. Kotb M., Norrby-Teglund A., McGeer A., et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002, 8(12):1398-1404.
27. Musser J.M., Hauser A.R., Kim M.H., et al. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 1991, 88:2668-2672.
28. Wharton M., Chorba T.L., Vogt R.L., et al. Case definitions for public health surveillance. MMWR Recomm Rep 1990, 39:1-43.
29. Hajjeh R.A., Reingold A., Weil A., et al. Toxic shock syndrome in the United States: surveillance update, 1979 1996. Emerg Infect Dis 1999, 5:807-810.
30. Broome C.V. Epidemiology of toxic shock syndrome in the United States: overview. Rev Infect Dis 1989, 11(Suppl 1):S14-S21.
31. Adams E.M., Gudmundsson S., Yocum D.E., et al. Streptococcal myositis. Arch Intern Med 1985, 145:1020-1023.
32. Kaul R., McGeer A., Low D.E., et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997, 103:18-24.
33. Laupland K.B., Davies H.D., Low D.E., et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 2000, 105:E60.
34. Haywood C.T., McGeer A., Low D.E. Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg 1999, 103:1567-1573.
35. Nuwayhid Z.B., Aronoff D.M., Mulla Z.D. Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Ann Epidemiol 2007, 17:878-881.
36. Bryant A.E., Bayer C.R., Huntington J.D., et al. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. JInfect Dis 2006, 193:1685-1692.
37. Muller M.P., Low D.E., Green K.A., et al. Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003, 163:467-472.
38. Thulin P., Johansson L., Low D.E., et al. Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med 2006, 3:e53.
39. Kim K.T., Kim Y.J., Won L.J., et al. Can necrotizing infectious fasciitis be differentiated from nonnecrotizing infectious fasciitis with MR imaging?. Radiology 2011, 259:816-824.
40. Malghem J., Lecouvet F.E., Omoumi P., et al. Vande Berg BC. Necrotizing fasciitis: contribution and limitations of diagnostic imaging. Joint Bone Spine 2012, 80(2):146-154.
41. Stamenkovic I., Lew P.D. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. NEngl J Med 1984, 310:1689-1693.
42. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
43. Brosnahan A.J., Schlievert P.M. Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome. FEBS J 2011, 278:4649-4667.
44. Norrby-Teglund A., Thulin P., Gan B.S., et al. Evidence for superantigen involvement in severe group A streptococcal tissue infections. JInfect Dis 2001, 184:853-860.
45. Beyersdorf N., Hanke T., Kerkau T., et al. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis 2005, 64(Suppl 4):iv91-iv95.
46. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. NEngl J Med 2006, 355:1018-1028.
47. Herwald H., Cramer H., Morgelin M., et al. Mprotein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004, 116:367-379.
48. Johansson L., Thulin P., Low D.E., et al. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clin Infect Dis 2010, 51:58-65.
49. Linder A., Akesson P., Inghammar M., et al. Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. Crit Care 2012, 16:R90.
50. Johansson L., Linner A., Sunden-Cullberg J., et al. Neutrophil-derived hyperresistinemia in severe acute streptococcal infections. JImmunol 2009, 183:4047-4054.
51. Soehnlein O., Oehmcke S., Ma X., et al. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. Eur Respir J 2008, 32:405-412.
52. Johansson L., Thulin P., Sendi P., et al. Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infect Immun 2008, 76:3399-3404.
53. Norrby-Teglund A., Chatellier S., Low D.E., et al. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 2000, 30:3247-3255.
54. Stevens D.L. Group A streptococcal sepsis. Curr Infect Dis Rep 2003, 5:379-386.
55. Holm S.E., Norrby A., Bergholm A.M., et al. Aspects of pathogenesis of serious group A streptococcal infections in Sweden. JInfect Dis 1992, 166:31-37.
56. Basma H. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 1998, 66:2279-2283.
57. Norrby-Teglund A., Kaul R., Low D.E., et al. Evidence for the presence of streptococcal superantigen neutralizing antibodies in normal polyspecific IgG (IVIG). Infect Immun 1996, 64:5395-5398.
58. Norrby-Teglund A., Kaul R., Low D.E., et al. Plasma from patients with severe group A streptococcal infections treated with normal polyspecific IgG (IVIG) inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. JImmunol 1996, 156:3057-3064.
59. Skansen-Saphir U., Andersson J., Bjorck L., et al. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994, 24:916-922.
60. Kaul R., McGeer A., Norrby-Teglund A., et al. Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome-a comparative observational study. Clin Infect Dis 1999, 28:800-807.
61. Darenberg J., Ihendyane N., Sjolin J., et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003, 37:333-340.
62. Norrby-Teglund A., Muller M.P., McGeer A., et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005, 37:166-172.
63. Beilman G.J., Dunn D. Surgical infections. Schwartz's principles of surgery 2010, 113-133. McGraw-Hill, New York. F.C. Brunicardi, D.K. Andersoen, T.R. Billiar (Eds.).
64. Pasternack M.S., Swartz M.N. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. Principles and practice of infectious diseases 2010, 1289-1312. Churchill Livingstone Elsevier, Philadelphia. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
65. Stevens D.L. Infections of the skin muscles, and soft tissues. Harrison's principles of internal medicine 2012, McGraw-Hill, New York. D.L. Longo, A.S. Fauci, D.L. Kasper (Eds.).
66. May A.K. Skin and soft tissue infections: the new surgical infection society guidelines. Surg Infect (Larchmt) 2011, 12:179-184.
67. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008, 2008(36):296-327.
68. Olsen R.J., Musser J.M. Molecular pathogenesis of necrotizing fasciitis. Annu Rev Pathol 2010, 5:1-31.
69. Schurr M., Engelhardt S., Helgerson R. Limb salvage for streptococcal gangrene of the extremity. Am J Surg 1998, 175:213-217.
70. Kotb M. Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Curr Opin Microbiol 1998, 1:56-65.
71. Cohen J. Shock factor shed by microbe. Nat Med 2004, 10:342-343.
72. Mier J., Leon E.L., Castillo A., et al. Early versus late necrosectomy in severe necrotizing pancreatitis. Am J Surg 1997, 173:71-75.
73. Freeman M.L., Werner J., van Santvoort H.C., et al. Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. Pancreas 2012, 41:1176-1194.
74. Rea W.J., Wyrick W.J. Necrotizing fasciitis. Ann Surg 1970, 172:957-964.
75. Majeski J.A., Alexander J.W. Early diagnosis, nutritional support, and immediate extensive debridement improve survival in necrotizing fasciitis. Am J Surg 1983, 145:784-787.
76. Freischlag J.A., Ajalat G., Busuttil R.W. Treatment of necrotizing soft tissue infections. The need for a new approach. Am J Surg 1985, 149:751-755.
77. Ward R.G., Walsh M.S. Necrotizing fasciitis: 10 years' experience in a district general hospital. Br J Surg 1991, 78:488-489. [see comments].
78. Wang K.C., Shih C.H. Necrotizing fasciitis of the extremities. JTrauma 1992, 32:179-182.
79. Voros D., Pissiotis C., Georgantas D., et al. Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. Br J Surg 1993, 80:1190-1191.
80. McHenry C.R., Piotrowski J.J., Petrinic D., et al. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995, 221:558-563.
81. Elliott D.C., Kufera J.A., Myers R.A. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 1996, 224:672-683.
82. Majeski J., Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J 1997, 90:1065-1068.
83. Bilton B.D., Zibari G.B., McMillan R.W., et al. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998, 64:397-400.
84. Wong C.H., Chang H.C., Pasupathy S., et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. JBone Joint Surg Am 2003, 85-A:1454-1460.
85. Gunter O.L., Guillamondegui O.D., May A.K., et al. Outcome of necrotizing skin and soft tissue infections. Surg Infect (Larchmt) 2008, 9:443-450.
86. Bucca K., Spencer R., Orford N., et al. Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study. ANZ J Surg 2012, 83(5):365-370.
87. Boyer A., Vargas F., Coste F., et al. Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management. Intensive Care Med 2009, 35:847-853.
88. Kobayashi L., Konstantinidis A., Shackelford S., et al. Necrotizing soft tissue infections: delayed surgical treatment is associated with increased number of surgical debridements and morbidity. JTrauma 2011, 71:1400-1405.
89. Kao L.S., Lew D.F., Arab S.N., et al. Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study. Am J Surg 2011, 202:139-145.
90. Pakula A.M., Kapadia R., Freeman B., et al. A3-year experience with necrotizing fasciitis: favorable outcomes despite operative delays in a busy acute care hospital. Am Surg 2012, 78:1059-1062.